Patent ID: 6673812
Filing Date: 2004-01-06
Classification: A61K,A61P,Y10S

Abstract:
A method for the treatment of glaucoma, which comprises administering an effective amount of a compound having a Rho kinase inhibitory activity to a patient in need thereof, wherein the compound having the Rho kinase inhibitory activity is an amide compound of formula (Iâ€²): whereinRaâ€² is a group of the formula whereinRâ€² is hydrogen, alkyl, or cycloalkyl, cycloalkylalkyl, phenyl or aralkyl, which optionally has a substitutent on the ring, R1 is hydrogen, alkyl, or cycloalkyl, cycloalkylalkyl, phenyl or aralkyl, which optionally has a substituent on the ring, or Râ€² and R1 in combination form, together with the adjacent nitrogen atom, a heterocycle optionally having, in the ring, oxygen atom, sulfur atom or optionally substituted nitrogen atom, R2 is hydrogen or alkyl, R3 and R4 are the same or different and each is hydrogen, alkyl, aralkyl, halogen, nitro, amino, alkylamino, acylamino, hydroxy, alkoxy, aralkyloxy, cyano, acyl, mercapto, alkylthio, aralkylthio, carboxy, alkoxycarbonyl, carbamoyl, alkylcarbamoyl or azide, and A is a group of the formula whereinR10 and R11 are the same or different and each is hydrogen, alkyl, haloalkyl, aralkyl, hydroxyalkyl, carboxy or alkoxycarbonyl, or R10 and R11 in combination form, together with the adjacent carbon atom, a cycloalkyl, and l, m and n are each 0 or an integer of 1-3,Rb is hydrogen, an alky, an aralkyl, an aminoalkyl or a mono- or dialkylaminoalkyl; and Rc is an optionally substituted heterocycle containing nitrogen, an isomer thereof or a pharmaceutically acceptable acid addition salt thereof.